Ziconotide is a 25-amino-acid peptide copied from the venom of a fish-hunting cone snail. It blocks N-type calcium channels on pain-carrying nerves. This guide covers its structure, mechanism, FDA-labeled use, trial evidence and its boxed warning. Sources were checked on November 17, 2026.
Quick answer: Ziconotide is a prescription non-opioid pain drug sold as Prialt. Its label covers severe chronic pain in adults who meet specific criteria, including not responding to or tolerating other treatment. It carries a boxed warning for severe psychiatric symptoms and neurological impairment. It is contraindicated in people with a history of psychosis.
Vitrapep does not sell ziconotide; this page is a reference summary of published research and regulatory information.
What is ziconotide?
The Prialt label states: “Ziconotide is a 25 amino acid, polybasic peptide containing three disulfide bridges” (Prialt label, 2026). Disulfide bridges are bonds between pairs of cysteine amino acids that fold the chain into a compact shape. Polybasic means it carries several positive charges.
The label calls it “a synthetic equivalent of a naturally occurring conopeptide found in the piscivorous marine snail, Conus magus.” Piscivorous means fish-eating. PubChem lists omega-conotoxin MVIIA and SNX 111 among its synonyms. It gives the formula as C102H172N36O32S7 and the molecular weight as 2,639.2 g/mol (PubChem CID 16135415). See our peptide primer and guide to peptide types for the basics.
Drugs@FDA lists the original approval of Prialt (NDA 021060) on December 28, 2004 (Drugs@FDA). It now names Esteve as the company.
Ziconotide: key facts
| Fact | Detail |
|---|---|
| Structure type | 25-amino-acid peptide with three disulfide bridges; synthetic copy of a Conus magus conopeptide |
| Class | N-type calcium channel blocker (omega-conotoxin) |
| Molecular formula | C102H172N36O32S7 |
| Molecular weight | 2,639.2 g/mol |
| First FDA approval | December 28, 2004 (Prialt, NDA 021060) |
| Brand names (US) | Prialt |
How does ziconotide work?
Nerves pass pain signals across junctions called synapses. To send the signal, calcium must flow into the nerve ending through channels. MeSH calls omega-conotoxins “a family of structurally related neurotoxic peptides from mollusk venom.” They block calcium entry at nerve endings (MeSH, 2000).
The Prialt label states that ziconotide “binds to N-type calcium channels located on the primary nociceptive (A-δ and C) afferent nerves.” These are the nerve fibers that carry pain. The label notes that the mechanism in humans has not been established. Animal results suggest that blocking these channels cuts the release of excitatory signaling chemicals from pain nerve endings. The label also states that “ziconotide does not bind to opioid receptors and its pharmacological effects are not blocked by opioid antagonists.”
What is ziconotide approved for?
The Prialt label lists one indication: “the management of severe chronic pain in adult patients” who need the specialized delivery approach the label describes. They must also be “intolerant of or refractory to other treatment,” such as standard pain medicines and adjunctive therapies.
The label lists two contraindications: known hypersensitivity to ziconotide or its formulation, and “a pre-existing history of psychosis.”
What did the key trials show?
Laboratory discovery. In 1985, Olivera and colleagues described peptide toxins from fish-hunting cone snails. Among them were omega-conotoxins that block calcium entry into nerve terminals (Olivera et al., 1985). In 1987, the same group purified omega-conotoxin MVIIA from Conus magus, sequenced it and made it synthetically. Their binding studies used brain tissue in vitro (Olivera et al., 1987).
Human trials. The Prialt label describes three double-blind, placebo-controlled, multicenter studies in 457 adults with severe chronic pain. In all, 268 received ziconotide and 189 placebo.
In the study the label details, the primary measure was the mean percent change in a visual analog pain score from baseline. Pain scores improved 12% with ziconotide and 5% with placebo at week 3. The 95% CI for the difference was 0.4% to 13%. Patients with at least 30% improvement made up 16% of the ziconotide group and 12% of the placebo group. ClinicalTrials.gov also lists a completed 220-patient Elan trial in severe chronic pain (NCT00047749).
What side effects does the label list?
The Prialt label has a boxed warning. It states: “Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT.” It calls for frequent checks for “cognitive impairment, hallucinations, or changes in mood or consciousness.” It also states that Prialt is contraindicated in patients with a preexisting history of psychosis.
The most frequently reported adverse reactions, in 25% or more of trial patients, were dizziness, nausea, confusional state and nystagmus (involuntary eye movements). Label warnings also cover meningitis and other infections, reduced consciousness and raised creatine kinase (a muscle enzyme). They also cover opiate withdrawal and limits on driving or operating machinery.
What is ziconotide’s regulatory status, and how is it used in research?
Ziconotide is a prescription drug in the United States. DailyMed lists Prialt labels from Esteve Pharmaceuticals and TerSera Therapeutics. The current Esteve label was revised in August 2026.
In the laboratory, omega-conotoxins have served as probes of calcium channels. The 1987 Olivera study proposed using omega-conotoxin MVIIA together with a related toxin, GVIA, to tell neuronal calcium channel subtypes apart. Clinical research continues as well: ClinicalTrials.gov lists OP2C, an observational study of Prialt in clinical practice, as recruiting (NCT04321408).
Frequently asked questions about ziconotide
Is ziconotide a peptide?
Yes. The label calls it a 25 amino acid peptide with three disulfide bridges.
Where does ziconotide come from?
It is a synthetic copy of a conopeptide from the fish-eating cone snail Conus magus. PubChem lists omega-conotoxin MVIIA as a synonym.
When was ziconotide approved?
Drugs@FDA lists the original approval of Prialt on December 28, 2004.
Is ziconotide an opioid?
No. The label calls Prialt “a non-opioid and non-NSAID analgesic agent.” It blocks N-type calcium channels and does not bind opioid receptors. The label covers patients who do not respond to or cannot tolerate other treatment.
Does ziconotide have a boxed warning?
Yes. It warns of severe psychiatric symptoms and neurological impairment, and the drug is contraindicated in people with a history of psychosis.
What to know now
- Structure: 25 amino acids, three disulfide bridges; 2,639.2 g/mol.
- Approval: Prialt, December 28, 2004; prescription only.
- Mechanism: binds N-type calcium channels on pain-carrying nerve fibers.
- Evidence: three placebo-controlled trials in 457 adults; 12% vs 5% pain score improvement in the detailed study.
- Label: severe chronic pain in adults intolerant of or refractory to other treatment.
- Safety: boxed warning for psychiatric symptoms and neurological impairment.
What we’re watching
The OP2C observational study, which lists an estimated primary completion in September 2027. Further Prialt label revisions on DailyMed. Related guides: zilucoplan, trofinetide and icatibant.